Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
Trial details
- Registry ID
- NCT04229979
- Phase
- Phase 3
Drug identity has not yet been verified against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2NCT04229979 | Sellas Life Sciences Group | Phase 3 | Active not recruiting | 2025-12Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |